Q2 2025 Newsletter

Dear Viska investors & supporters,

Viska had a very positive second quarter of 2025. We conducted an in vivo study using an immune-incompetent mouse model. Glioblastoma tumors were treated with our VISK-103 fusion protein and compared to treatment with control. At the end of the pre-specified study termination date, all VISK-103 treated mice were alive with a reduced tumor burden, and the mice treated with the control vehicle were all sacrificed due to tumor size. In Q3, we will extend our studies by treating immune competent mice with colorectal tumors. In addition, we will carry out PK and drug distribution studies in mice.

BIO international, the annual gathering of the biotech industry, took place in Boston in June. The Viska team had a great outing: hosting our mixer for over 150 people in the Start Up community sponsored by Impact Ventures, Thermo Fisher Scientific, Cooley, Lab Central and Wolf, Greenfield andwinning a major prize at the Luminescent event. We met with numerous potential investors and partners. We mark BIO as a gold star event for Viska Bio – looking forward to reconnecting with everyone when BIO moves to San Deigo next June.

Check out the rest of our newsletter here.

Best regards,

Eric